BCTXW (BriaCell Therapeutics) Receipts from Customers

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCTXW BriaCell Therapeutics Corp BCTXW
29 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics Receipts from Customers?

Receipts from Customers only applicable to companies reporting Cash Flow from Operations in direct method.

BCTXW
29GF Score
BriaCell Therapeutics Corp BCTXW
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company based in Canada that develops targeted immunotherapies for cancer. Its lead program, Bria-IMT, is a cell-based immunotherapy in late-stage clinical development for advanced breast cancer, and is being studied in combination with immune checkpoint inhibitors. The company is also developing Bria-OTS, a personalized off-the-shelf immunotherapy platform intended for breast and prostate cancers, and Bria-OTS+ and Bria-IMT-based approaches for other tumor types. BriaCell conducts its clinical trials primarily in the United States, often in collaboration with academic and research institutions, and has no approved products or product revenue; it funds operations through equity financings, research grants, and partnership arrangements. The company's goal is to advance its immunotherapy candidates through clinical trials toward regulatory approval and eventual commercialization.
29GF Score

Get the complete analysis for BCTXW

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price